312 related articles for article (PubMed ID: 34063247)
41. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.
Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S
J Genet; 2021; 100(1):. PubMed ID: 33707363
[TBL] [Abstract][Full Text] [Related]
42. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells.
Matsuyama S; Nao N; Shirato K; Kawase M; Saito S; Takayama I; Nagata N; Sekizuka T; Katoh H; Kato F; Sakata M; Tahara M; Kutsuna S; Ohmagari N; Kuroda M; Suzuki T; Kageyama T; Takeda M
Proc Natl Acad Sci U S A; 2020 Mar; 117(13):7001-7003. PubMed ID: 32165541
[TBL] [Abstract][Full Text] [Related]
43. Computational and in vitro experimental analyses of the anti-COVID-19 potential of Mortaparib and MortaparibPlus.
Kumar V; Sari AN; Meidinna HN; Dhanjal JK; Subramani C; Basu B; Kaul SC; Vrati S; Sundar D; Wadhwa R
Biosci Rep; 2021 Oct; 41(10):. PubMed ID: 34647577
[TBL] [Abstract][Full Text] [Related]
44. The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer.
Mollica V; Rizzo A; Massari F
Future Oncol; 2020 Sep; 16(27):2029-2033. PubMed ID: 32658591
[No Abstract] [Full Text] [Related]
45. Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management.
D'Amico F; Baumgart DC; Danese S; Peyrin-Biroulet L
Clin Gastroenterol Hepatol; 2020 Jul; 18(8):1663-1672. PubMed ID: 32278065
[TBL] [Abstract][Full Text] [Related]
46. ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients.
Ravaioli S; Tebaldi M; Fonzi E; Angeli D; Mazza M; Nicolini F; Lucchesi A; Fanini F; Pirini F; Tumedei MM; Cerchione C; Viale P; Sambri V; Martinelli G; Bravaccini S
Cell Transplant; 2020; 29():963689720968749. PubMed ID: 33108902
[TBL] [Abstract][Full Text] [Related]
47. Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection?
Gupta VK; Murthy MK; Patil S
Curr Drug Targets; 2021; 22(10):1149-1157. PubMed ID: 33243116
[TBL] [Abstract][Full Text] [Related]
48. Precision therapeutic targets for COVID-19.
Krumm ZA; Lloyd GM; Francis CP; Nasif LH; Mitchell DA; Golde TE; Giasson BI; Xia Y
Virol J; 2021 Mar; 18(1):66. PubMed ID: 33781287
[TBL] [Abstract][Full Text] [Related]
49. Existence of SARS-CoV-2 Entry Molecules in the Oral Cavity.
Sakaguchi W; Kubota N; Shimizu T; Saruta J; Fuchida S; Kawata A; Yamamoto Y; Sugimoto M; Yakeishi M; Tsukinoki K
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825469
[TBL] [Abstract][Full Text] [Related]
50. Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and identification of putative modulators.
Gkogkou E; Barnasas G; Vougas K; Trougakos IP
Redox Biol; 2020 Sep; 36():101615. PubMed ID: 32863223
[TBL] [Abstract][Full Text] [Related]
51. Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection.
Wettstein L; Weil T; Conzelmann C; Müller JA; Groß R; Hirschenberger M; Seidel A; Klute S; Zech F; Prelli Bozzo C; Preising N; Fois G; Lochbaum R; Knaff PM; Mailänder V; Ständker L; Thal DR; Schumann C; Stenger S; Kleger A; Lochnit G; Mayer B; Ruiz-Blanco YB; Hoffmann M; Sparrer KMJ; Pöhlmann S; Sanchez-Garcia E; Kirchhoff F; Frick M; Münch J
Nat Commun; 2021 Mar; 12(1):1726. PubMed ID: 33741941
[TBL] [Abstract][Full Text] [Related]
52. Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research.
Simmons G; Zmora P; Gierer S; Heurich A; Pöhlmann S
Antiviral Res; 2013 Dec; 100(3):605-14. PubMed ID: 24121034
[TBL] [Abstract][Full Text] [Related]
53. H
Yang G
Am J Physiol Cell Physiol; 2020 Aug; 319(2):C244-C249. PubMed ID: 32515982
[TBL] [Abstract][Full Text] [Related]
54. Blockade of TMPRSS2-mediated priming of SARS-CoV-2 by lactoferricin.
Ohradanova-Repic A; Skrabana R; Gebetsberger L; Tajti G; Baráth P; Ondrovičová G; Praženicová R; Jantova N; Hrasnova P; Stockinger H; Leksa V
Front Immunol; 2022; 13():958581. PubMed ID: 36081512
[TBL] [Abstract][Full Text] [Related]
55. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated.
Wambier CG; Goren A
J Am Acad Dermatol; 2020 Jul; 83(1):308-309. PubMed ID: 32283245
[TBL] [Abstract][Full Text] [Related]
56. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2.
Hoffmann M; Mösbauer K; Hofmann-Winkler H; Kaul A; Kleine-Weber H; Krüger N; Gassen NC; Müller MA; Drosten C; Pöhlmann S
Nature; 2020 Sep; 585(7826):588-590. PubMed ID: 32698190
[TBL] [Abstract][Full Text] [Related]
57. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells.
Zhao H; Lu L; Peng Z; Chen LL; Meng X; Zhang C; Ip JD; Chan WM; Chu AW; Chan KH; Jin DY; Chen H; Yuen KY; To KK
Emerg Microbes Infect; 2022 Dec; 11(1):277-283. PubMed ID: 34951565
[TBL] [Abstract][Full Text] [Related]
58. Structure and activity of human TMPRSS2 protease implicated in SARS-CoV-2 activation.
Fraser BJ; Beldar S; Seitova A; Hutchinson A; Mannar D; Li Y; Kwon D; Tan R; Wilson RP; Leopold K; Subramaniam S; Halabelian L; Arrowsmith CH; Bénard F
Nat Chem Biol; 2022 Sep; 18(9):963-971. PubMed ID: 35676539
[TBL] [Abstract][Full Text] [Related]
59. Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2.
Li Y; Wang K; Sun H; Wu S; Wang H; Shi Y; Li X; Yan H; Yang G; Wu M; Li Y; Ding X; Si S; Jiang J; Du Y; Li Y; Hong B
Antiviral Res; 2023 Jun; 214():105606. PubMed ID: 37076089
[TBL] [Abstract][Full Text] [Related]
60. SARS-CoV-2 host tropism: An in silico analysis of the main cellular factors.
Rangel HR; Ortega JT; Maksoud S; Pujol FH; Serrano ML
Virus Res; 2020 Nov; 289():198154. PubMed ID: 32918944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
